Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-27 00:00 | 2025-11-25 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $1,095.35 | 147,061 | $161,082,634 | 92,212,610 |
| 2025-11-27 00:43 | 2025-11-24 | MAIA | MAIA Biotechnology, Inc. | Smith Stan | Director | BUY | $0.98 | 25,000 | $24,600 | 1,349,289 |
| 2025-11-27 00:30 | 2025-11-24 | NUVL | Nuvalent, Inc. | Shair Matthew | Director | SELL | $109.37 | 7,500 | $820,274 | 201,672 |
| 2025-11-27 01:55 | 2025-11-25 | NUVB | Nuvation Bio Inc. | Liu Dongfang | Officer | OPT+S | $7.75 | 20,000 | $155,000 | 18,000 |
| 2025-11-27 01:01 | 2025-11-24 | RPRX | Royalty Pharma plc | Coyne Terrance P. | Officer | SELL | $38.55 | 69,582 | $2,682,504 | 51,010 |
| 2025-11-26 22:58 | 2025-11-26 | ABCL | AbCellera Biologics Inc. | Montalbano John S. | Director | BUY | $3.57 | 50,000 | $178,460 | 221,000 |
| 2025-11-27 00:07 | 2025-11-26 | RCUS | Arcus Biosciences, Inc. | Goeltz II Robert C. | Officer | SELL | $25.00 | 5,000 | $125,000 | 87,138 |
| 2025-11-27 00:06 | 2025-11-24 | STOK | Stoke Therapeutics, Inc. | Krainer Adrian R. | Director | SELL | $29.72 | 40,472 | $1,202,719 | 323,774 |
| 2025-11-27 00:05 | 2025-11-24 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | BUY | $39.97 | 949 | $37,933 | 364,100 |
| 2025-11-27 00:30 | 2025-11-25 | ADTX | Aditxt Inc. | Pankovcin Corinne | Officer | SELL | $3.20 | 1 | $3 | 0 |
| 2025-11-27 05:30 | 2025-11-24 | CRMD | CorMedix Inc. | Dillione Janet | Director | OPT+S | $9.93 | 26,343 | $261,586 | 48,473 |
| 2025-11-27 00:02 | 2025-11-24 | OCUL | OCULAR THERAPEUTIX, INC | Nayak Sanjay | Officer | SELL | $12.04 | 1,878 | $22,611 | 277,860 |
| 2025-11-27 00:02 | 2025-11-24 | OCUL | OCULAR THERAPEUTIX, INC | Dugel Pravin | Director, Officer | SELL | $12.04 | 19,530 | $235,141 | 3,157,960 |
| 2025-11-27 00:01 | 2025-11-24 | OCUL | OCULAR THERAPEUTIX, INC | Kaiser Peter | Officer | SELL | $12.02 | 3,007 | $36,144 | 191,433 |
| 2025-11-27 00:01 | 2025-11-24 | OCUL | OCULAR THERAPEUTIX, INC | Heier Jeffrey S. | Officer | SELL | $12.04 | 3,469 | $41,767 | 245,940 |
| 2025-11-27 02:41 | 2025-11-24 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Director | SELL | $44.55 | 108,073 | $4,814,209 | 3,596,886 |
| 2025-11-27 02:47 | 2025-11-24 | KALV | KalVista Pharmaceuticals, Inc. | Audhya Paul K. | Officer | OPT+S | $13.45 | 5,296 | $71,236 | 131,831 |
| 2025-11-27 02:50 | 2025-11-24 | KALV | KalVista Pharmaceuticals, Inc. | Piekos Brian | Officer | OPT+S | $13.45 | 4,471 | $60,139 | 10,529 |
| 2025-11-27 02:49 | 2025-11-24 | KALV | KalVista Pharmaceuticals, Inc. | Yea Christopher | Officer | OPT+S | $13.45 | 4,331 | $58,256 | 223,508 |
| 2025-11-27 02:46 | 2025-11-24 | KALV | KalVista Pharmaceuticals, Inc. | Palleiko Benjamin L | Director, Officer | OPT+S | $13.45 | 10,940 | $147,154 | 416,189 |
| 2025-11-27 01:21 | 2025-11-25 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $3.90 | 5,965 | $23,264 | 5,965 |
| 2025-11-27 02:24 | 2025-11-24 | ORGO | Organogenesis Holdings Inc. | NUSSDORF GLENN H | Director, 10% owner | SELL | $5.31 | 300,000 | $1,592,130 | 2,765,591 |
| 2025-11-27 00:01 | 2025-11-25 | PBH | Prestige Consumer Healthcare Inc. | BYOM JOHN E | Director | SELL | $59.35 | 3,000 | $178,050 | 51,594 |
| 2025-11-27 05:18 | 2025-11-24 | FOLD | AMICUS THERAPEUTICS, INC. | Castelli Jeff | Officer | OPT+S | $10.16 | 76,158 | $773,659 | 439,318 |
| 2025-11-27 05:17 | 2025-11-24 | FOLD | AMICUS THERAPEUTICS, INC. | Clark David Michael | Officer | SELL | $10.10 | 25,643 | $258,933 | 296,975 |
| 2025-11-27 05:17 | 2025-11-24 | FOLD | AMICUS THERAPEUTICS, INC. | Campbell Bradley L | Director, Officer | OPT+S | $10.04 | 14,587 | $146,522 | 1,137,282 |
| 2025-11-27 05:16 | 2025-11-24 | FOLD | AMICUS THERAPEUTICS, INC. | Rosenberg Ellen | Officer | OPT+S | $10.02 | 95,621 | $958,476 | 507,710 |
| 2025-11-27 00:31 | 2025-11-24 | INSM | INSMED Inc | ANDERSON ELIZABETH M | Director | SELL | $204.58 | 5,000 | $1,022,900 | 58,729 |
| 2025-11-27 01:22 | 2025-11-25 | CORT | CORCEPT THERAPEUTICS INC | Guyer William | Officer | SELL | $80.90 | 4,500 | $364,070 | 787 |
| 2025-11-27 00:30 | 2025-11-24 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $473.66 | 22,500 | $10,657,280 | 0 |
| 2025-11-27 00:31 | 2025-11-24 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $473.64 | 21,000 | $9,946,543 | 8,142 |
| 2025-11-27 00:30 | 2025-11-26 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $486.06 | 11,000 | $5,346,701 | 36,781 |
| 2025-11-27 01:20 | 2025-11-24 | PTCT | PTC THERAPEUTICS, INC. | Jacobson Allan Steven | Director | OPT+S | $82.00 | 26,000 | $2,132,018 | 17,451 |
| 2025-11-27 01:25 | 2025-11-25 | PTCT | PTC THERAPEUTICS, INC. | Almstead Neil Gregory | Officer | OPT+S | $83.44 | 71,928 | $6,001,931 | 100,625 |
| 2025-11-27 01:20 | 2025-11-24 | PTCT | PTC THERAPEUTICS, INC. | Almstead Neil Gregory | Officer | OPT+S | $80.18 | 35,572 | $2,852,031 | 100,625 |
| 2025-11-27 01:46 | 2025-11-25 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $43.97 | 12,320 | $541,673 | 33,840 |
| 2025-11-27 02:45 | 2025-11-24 | SION | Sionna Therapeutics, Inc. | ORBIMED ADVISORS LLC | Director | SELL | $44.55 | 108,073 | $4,814,209 | 3,596,886 |
| 2025-11-26 00:00 | 2025-11-24 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $1,068.52 | 142,307 | $152,058,089 | 92,359,671 |
| 2025-11-26 02:39 | 2025-11-24 | BCAX | Bicara Therapeutics Inc. | Raben David | Officer | OPT+S | $18.65 | 11,000 | $205,108 | 35,497 |
| 2025-11-26 02:40 | 2025-11-24 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | Director, Officer | OPT+S | $18.86 | 41,163 | $776,429 | 309,892 |
| 2025-11-26 02:42 | 2025-11-21 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | Officer | OPT+S | $18.54 | 18,400 | $341,075 | 145,355 |
| 2025-11-26 02:41 | 2025-11-21 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Director, Officer | OPT+S | $18.05 | 12,500 | $225,588 | 193,641 |
| 2025-11-26 00:15 | 2025-11-21 | MAIA | MAIA Biotechnology, Inc. | Vitoc Vlad | Director, Officer, 10% owner | BUY | $0.98 | 11,800 | $11,547 | 820,921 |
| 2025-11-26 00:01 | 2025-11-21 | ALMS | Alumis Inc. | Foresite Labs, LLC | 10% owner | BUY | $7.38 | 72,212 | $532,925 | 2,614,215 |
| 2025-11-26 00:05 | 2025-11-21 | VERA | Vera Therapeutics, Inc. | Carter Jason S | Officer | SELL | $27.82 | 3,864 | $107,498 | 49,136 |
| 2025-11-26 04:29 | 2025-11-25 | NKTR | NEKTAR THERAPEUTICS | Wilson Mark Andrew | Officer | SELL | $54.28 | 630 | $34,196 | 21,585 |
| 2025-11-26 00:17 | 2025-11-25 | ABT | Abbott Laboratories | Shroff Eric | Officer | SELL | $128.02 | 1,586 | $203,043 | 30,384 |
| 2025-11-26 00:02 | 2025-11-21 | ALMS | Alumis Inc. | Foresite Capital Management VI LLC | 10% owner | BUY | $7.38 | 72,212 | $532,925 | 2,614,215 |
| 2025-11-26 04:30 | 2025-11-25 | NKTR | NEKTAR THERAPEUTICS | Zalevsky Jonathan | Officer | SELL | $54.28 | 1,157 | $62,802 | 18,971 |
| 2025-11-26 02:27 | 2025-11-24 | ARQT | Arcutis Biotherapeutics Inc. | LIN SUE-JEAN | Director | OPT+S | $30.78 | 25,272 | $777,956 | 26,735 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.